Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
- 1 January 2012
- journal article
- clinical trial
- Published by Elsevier BV in Cancer Cell
- Vol. 21 (1), 82-91
- https://doi.org/10.1016/j.ccr.2011.11.023
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Receptor Tyrosine Kinase Inhibition, Hypertension, and ProteinuriaHypertension, 2010
- Adverse effects of anticancer agents that target the VEGF pathwayNature Reviews Clinical Oncology, 2009
- Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast CancerJournal of Clinical Oncology, 2008
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Angiogenesis as a therapeutic targetNature, 2005
- Evaluation of Basis Function and Linear Least Squares Methods for Generating Parametric Blood Flow Images Using 15O-Water and Positron Emission TomographyMolecular Imaging & Biology, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancerSeminars in Oncology, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Mechanisms of angiogenesis and arteriogenesisNature Medicine, 2000